RDY
Dr. Reddy's Laboratories LimitedNYSEHealthcare$13.32-1.11%ClosedMarket Cap: $11.09B
As of 2026-04-06
Valuation
P/E (TTM)
17.91
PEG
0.04
P/B
2.72
P/S
2.93
EV/EBITDA
12.09
DCF Value
$-99.13
FCF Yield
2.8%
Div Yield
0.7%
Margins & Returns
Gross Margin
55.2%
Operating Margin
19.3%
Net Margin
16.4%
ROE
16.0%
ROA
12.6%
ROIC
11.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2026 | $87.27B | 53.6% | $14.24B | $12.10B | $14.52 | — |
| Q2 2026 | $88.05B | 54.7% | $17.51B | $14.37B | $17.25 | $0.09 |
| Q1 2026 | $85.45B | 56.9% | $17.48B | $14.18B | $17.02 | — |
| Q4 2025 | $85.06B | 55.6% | $17.65B | $15.94B | $19.10 | — |
| FY 2025 | $325.54B | 58.5% | $71.84B | $56.54B | $67.77 | $0.48 |
| Q3 2025 | $83.59B | 58.7% | $18.72B | $14.13B | $16.94 | — |
| Q2 2025 | $80.16B | 59.6% | $17.55B | $12.55B | $15.05 | $0.48 |
| Q1 2025 | $76.73B | 60.4% | $17.93B | $13.92B | $16.69 | — |
| Q4 2024 | $70.83B | 58.6% | $14.96B | $13.07B | $15.67 | — |
| FY 2024 | $279.16B | 58.6% | $67.73B | $55.68B | $66.80 | $0.49 |
| Q3 2024 | $72.15B | 58.5% | $17.27B | $13.79B | $16.54 | — |
| Q2 2024 | $832.2M | 56.4% | $175.7M | $179.0M | $17.76 | $0.49 |